Peptides for Anxiety: What the Research Shows

Anxiety disorders affect over 40 million adults in the United States, making them the most common category of mental illness. Standard treatments — SSRIs, benzodiazepines, cognitive behavioral therapy — work well for many people, but not everyone responds adequately. Side effects, dependence risk, and incomplete relief drive ongoing interest in alternative approaches, including peptide therapy.

Several peptides have demonstrated anxiolytic (anxiety-reducing) properties in preclinical and limited clinical research. Selank, the most studied in this category, is already approved as an anxiolytic medication in Russia. Others like semax, BPC-157, and oxytocin affect neurological pathways involved in stress response and emotional regulation through distinct mechanisms. But the evidence base varies dramatically between compounds, and most of what we know comes from animal models or small human studies.

This is not a guide on replacing your psychiatrist or ditching your medication. It is a look at what the research actually says about peptides and anxiety — where the data is strong, where it is weak, and what remains unknown.

Key takeaways

• Selank has the strongest evidence for anxiety, with GABAergic and enkephalin-modulating mechanisms and clinical approval in Russia
• Semax primarily targets cognitive function but may reduce anxiety secondary to chronic stress via BDNF upregulation
• BPC-157 shows anxiolytic effects in rodent studies through dopaminergic and serotonergic system modulation, but lacks human anxiety data
• Oxytocin reduces social anxiety in specific contexts, though effects are inconsistent across studies
• Most evidence is preclinical — peptides should not replace evidence-based anxiety treatments like therapy and prescribed medications

Table of contents

1. How anxiety works at the neurochemical level
2. Selank: the most studied anxiolytic peptide
3. Semax: cognitive support and stress resilience
4. BPC-157: preclinical anxiolytic effects
5. Oxytocin: the social anxiety connection
6. DSIP: anxiety through the sleep pathway
7. Comparing peptides for anxiety
8. Safety, limitations, and important caveats
9. FAQ
10. Sources

How anxiety works at the neurochemical level

Anxiety is not a single malfunction. It involves the interplay of multiple neurotransmitter systems — primarily GABA, serotonin, norepinephrine, and the hypothalamic-pituitary-adrenal (HPA) axis that governs cortisol release. Understanding these systems helps explain why different peptides may affect anxiety through different doors.

GABA (gamma-aminobutyric acid) is the brain’s primary inhibitory neurotransmitter. When GABA signaling is insufficient, neural circuits become overactive, producing the racing thoughts, hypervigilance, and physical tension characteristic of anxiety. Benzodiazepines work by enhancing GABA activity — they are effective but carry significant dependence risk [1].

Serotonin modulates mood, sleep, and emotional processing. SSRIs work by increasing serotonin availability at synapses. The endogenous opioid system, particularly enkephalins, also plays a role in emotional regulation — enkephalins reduce the subjective experience of distress without the respiratory depression risks of exogenous opioids [2].

Brain-derived neurotrophic factor (BDNF) is increasingly recognized as relevant to anxiety. BDNF supports neuronal survival and synaptic plasticity, and low BDNF levels are associated with both anxiety disorders and depression, as well as impaired stress resilience. Chronic stress reduces BDNF expression in the hippocampus, creating a cycle where stress makes the brain less capable of adapting to future stress [3].

Each of the peptides discussed below targets one or more of these systems.

Selank: the most studied anxiolytic peptide

Selank is a synthetic analog of tuftsin, an immunomodulatory peptide naturally produced by the spleen. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, selank has been approved in Russia as an anxiolytic and nootropic medication since 2009 [4].

Mechanism of action

Selank’s anxiolytic effects operate through several converging pathways. The most significant is its influence on the GABAergic system. A detailed pharmacology review in the Journal of Clinical Pharmacology (2021) detailed selank’s GABAergic mechanisms and its classification among sedative-hypnotic agents, noting its favorable profile compared to conventional benzodiazepines [17]. Research demonstrates that selank modulates GABA-A receptor activity, enhancing inhibitory neurotransmission in a manner that reduces anxiety without the sedation or cognitive impairment associated with benzodiazepines [4].

Perhaps more uniquely, selank increases the concentration of leu-enkephalin in the brain. Enkephalins are endogenous opioid peptides that modulate pain perception and emotional responses. By stabilizing enkephalin levels — specifically by inhibiting the enzymes that degrade them — selank produces an anxiolytic and mild mood-elevating effect through the body’s own opioid system [5]. This is distinct from exogenous opioid drugs because it works within the physiological range of endogenous signaling.

Selank also influences serotonin metabolism. Studies show it affects the expression of genes involved in serotonin transport and receptor binding, particularly in the hippocampus and frontal cortex [6]. A 2018 review in Protein and Peptide Letters further characterized selank’s molecular mechanisms of anxiolytic action, describing how the heptapeptide modulates multiple neurotransmitter systems simultaneously [19]. This dual GABAergic-serotonergic activity may explain why selank has been described as having “antianxiety, antidepressant, and antiasthenic properties” in the research literature [4]. For more on selank’s potential role in mood disorders, see our guide on peptides for depression.

Clinical evidence

The clinical data on selank comes primarily from Russian studies. A randomized controlled trial comparing selank to the benzodiazepine medazepam in patients with generalized anxiety disorder found comparable anxiolytic efficacy, with selank demonstrating a more favorable side effect profile — no sedation, no cognitive impairment, and no withdrawal symptoms upon discontinuation [7].

Additional clinical studies have shown selank to be effective for anxiety associated with adjustment disorders, with onset of effects typically observed within the first week of treatment. The nootropic properties — improved attention, memory consolidation, and mental clarity — are considered secondary benefits that may further reduce anxiety by improving cognitive performance under stress [4].

Administration

Selank is typically administered intranasally at doses of 250-500 mcg per application, two to three times daily. The intranasal route provides rapid absorption and bypasses first-pass liver metabolism. Courses typically run 10-14 days, though some protocols extend longer.

Limitations

The major limitation is that nearly all clinical research on selank was conducted in Russia and published in Russian-language journals. While some studies have been translated and peer-reviewed, the body of evidence does not meet the standards that Western regulatory agencies require for drug approval. No large-scale, multicenter, placebo-controlled trials have been conducted outside of Russia.

Semax: cognitive support and stress resilience

Semax is a synthetic peptide based on the ACTH(4-10) fragment — a portion of adrenocorticotropic hormone that retains neurotropic activity without the hormonal effects of the full ACTH molecule. Like selank, it was developed in Russia and is approved there for neurological conditions.

How semax relates to anxiety

Semax is not primarily an anxiolytic. Its core mechanism is the upregulation of BDNF expression in the brain, particularly in the hippocampus and cortex [8]. A 2020 study using functional connectomic analysis revealed that both selank and semax produce measurable changes in brain connectivity patterns, providing neuroimaging evidence for their central nervous system effects [18]. This makes semax primarily a cognitive enhancer and neuroprotective agent. However, its relevance to anxiety comes through two pathways.

First, BDNF restoration. Chronic stress depletes BDNF, which impairs the brain’s ability to regulate emotional responses and adapt to new situations. By increasing BDNF levels, semax may help restore stress resilience — the capacity to experience stressful events without tipping into sustained anxiety [3]. This is not the same as directly reducing acute anxiety symptoms, but it addresses one of the biological substrates that makes people vulnerable to anxiety in the first place.

Second, semax has demonstrated effects on the serotonergic and dopaminergic systems. Research shows it modulates the expression of genes involved in serotonin and dopamine metabolism, which could contribute to mood stabilization [9]. For individuals whose anxiety is intertwined with cognitive fatigue, brain fog, or burnout — common in chronic stress scenarios and during perimenopause in women over 40 — semax may address both the cognitive and emotional components simultaneously.

Evidence base

Animal studies consistently demonstrate that semax increases BDNF mRNA expression and promotes neuronal survival under stress conditions [8]. In human studies conducted in Russia, semax has shown benefits for cognitive function in patients recovering from stroke and in healthy individuals under high cognitive load.

Specific anxiety outcome data from human trials is limited. The anxiolytic effects described in the literature are generally secondary observations in studies primarily measuring cognitive endpoints. This is an important distinction — semax may help with anxiety, but it has not been rigorously tested as an anxiety treatment.

Practical considerations

Semax is administered intranasally, typically at 200-600 mcg per dose, one to three times daily. For those interested in both cognitive enhancement and stress-related anxiety, semax and selank are sometimes used together, as their mechanisms are complementary. For more on cognitive applications, see our guide on peptides for cognitive function.

BPC-157: preclinical anxiolytic effects

BPC-157 (Body Protection Compound-157) is best known for its tissue-healing properties, but preclinical research has also identified significant effects on central neurotransmitter systems that are relevant to anxiety.

The dopamine and serotonin connection

BPC-157 interacts with both the dopaminergic and serotonergic systems in ways that go beyond simple receptor binding. Animal studies have demonstrated that BPC-157 can counteract behavioral changes induced by both dopamine agonists and antagonists, suggesting it acts as a modulator rather than a simple stimulant or inhibitor of these systems [10].

In rodent models, BPC-157 has reversed anxiety-like behaviors induced by various pharmacological challenges. Specifically, it has shown the ability to counteract the anxiogenic effects of dopamine system disruption and to normalize serotonin turnover in the brain [10]. The peptide appears to help restore homeostatic balance in these neurotransmitter systems rather than pushing them in one direction.

Anxiolytic data in animal models

Several rodent studies have evaluated BPC-157 using standard behavioral tests for anxiety, including the elevated plus maze and open field tests. In these models, BPC-157 administration produced anxiolytic effects comparable to those seen with conventional anxiolytic drugs, with animals spending more time in exposed areas and exhibiting fewer freezing behaviors [11].

BPC-157 has also demonstrated protective effects against the anxiety-inducing consequences of chronic stress paradigms in animals. Rats subjected to chronic unpredictable stress showed normalization of anxiety behaviors when treated with BPC-157, along with improvements in markers of HPA axis function [11].

The gap between rodent and human data

The anxiolytic evidence for BPC-157 is entirely preclinical. No human studies have specifically evaluated BPC-157 for anxiety or any psychiatric condition. While the rodent data is consistent and the mechanisms are plausible, translating these findings to clinical anxiety treatment in humans requires controlled trials that have not been conducted.

BPC-157 may be most relevant for individuals already using it for its better-known applications — gut healing, musculoskeletal recovery — who notice mood and anxiety improvements as secondary benefits. But prescribing BPC-157 specifically for anxiety would be getting well ahead of the evidence.

Oxytocin: the social anxiety connection

Oxytocin is a nine-amino-acid peptide produced in the hypothalamus and released by the posterior pituitary. Often called the “bonding hormone,” it plays established roles in social attachment, trust, and interpersonal connection. Its relationship to anxiety is specific and more complex than the label suggests.

Social anxiety and oxytocin

The strongest anxiety-related data for oxytocin involves social anxiety. Intranasal oxytocin administration has been shown to reduce amygdala reactivity to threatening social stimuli — faces expressing anger or fear — in functional MRI studies [12]. The amygdala is the brain’s threat detection center, and its hyperactivity is a hallmark of social anxiety disorder.

A 2012 meta-analysis found that intranasal oxytocin improved social cognition and reduced anxiety in social contexts, with moderate effect sizes [13]. Some studies have shown that oxytocin enhances the effectiveness of exposure therapy for social anxiety when administered before therapy sessions, suggesting it may work best as an adjunct to established treatments rather than a standalone intervention.

Limitations and inconsistencies

The oxytocin literature is marked by inconsistency. Effects vary significantly based on context, individual baseline oxytocin levels, gender, and the specific social situation being studied. Some studies have found that oxytocin can actually increase anxiety in certain contexts — particularly when the social environment is perceived as threatening or when individuals have histories of adverse social experiences [14].

Oxytocin also has a very short half-life (approximately 3-5 minutes in plasma), and the degree to which intranasal administration actually reaches relevant brain regions in meaningful concentrations remains debated. These pharmacokinetic challenges complicate both research and clinical application.

Current status

Oxytocin is used in some integrative and functional medicine practices for social anxiety and autism spectrum conditions. It is FDA-approved for obstetric indications (labor induction) but not for anxiety. Its use for anxiety-related purposes is off-label and should involve careful clinical supervision.

DSIP: anxiety through the sleep pathway

Delta sleep-inducing peptide (DSIP) is a nine-amino-acid peptide that was first isolated from rabbit brain tissue in 1977. Its primary action is the promotion of delta-wave (deep) sleep, but its relevance to anxiety comes through the well-established bidirectional relationship between sleep and anxiety.

The sleep-anxiety cycle

Poor sleep is both a symptom and a cause of anxiety. Sleep deprivation increases amygdala reactivity by up to 60% while simultaneously reducing connectivity between the amygdala and the prefrontal cortex — the brain region responsible for rational evaluation of threats [15]. This creates a vicious cycle: anxiety disrupts sleep, and disrupted sleep amplifies anxiety.

DSIP promotes deep, restorative sleep by modulating the ratio of sleep stages. Studies have shown it increases delta-wave sleep duration without the forced sedation or altered sleep architecture caused by benzodiazepines or Z-drugs [16]. By normalizing sleep patterns, DSIP may indirectly reduce anxiety through improved neural recovery and restored prefrontal-amygdala connectivity.

Evidence and practical use

Human studies on DSIP for sleep have shown modest improvements in sleep quality, particularly in individuals with chronic insomnia. The anxiolytic effects are inferred from sleep normalization rather than directly measured in anxiety-specific trials [16].

DSIP is typically administered via subcutaneous injection at doses of 100-200 mcg before bedtime. For more detail on peptides that target sleep, see our guide on peptides for sleep.

Comparing peptides for anxiety

Not all of these peptides target anxiety in the same way, and understanding the differences helps clarify which might be relevant in different situations.

Selank is the most direct anxiolytic — it reduces anxiety symptoms through GABA and enkephalin modulation, with clinical data supporting its use for generalized anxiety. It is the closest thing to a “peptide anxiolytic” in the group.

Semax is better suited for anxiety that co-occurs with cognitive decline, brain fog, or chronic stress burnout. Its BDNF-mediated effects build stress resilience over time rather than providing immediate relief.

BPC-157 is not a first-line approach to anxiety, but individuals using it for gut or musculoskeletal issues may experience anxiolytic benefits as a secondary effect of its neurotransmitter-modulating activity.

Oxytocin has a narrow application — specifically social anxiety — and works best as an adjunct to therapy rather than a standalone treatment.

DSIP addresses anxiety indirectly through sleep normalization and is most relevant for individuals whose anxiety is significantly worsened by insomnia.

Safety, limitations, and important caveats

General safety considerations

The peptides discussed in this guide have generally favorable safety profiles in the available research. Selank and semax have the most human safety data, largely because of their clinical use in Russia. BPC-157 has extensive animal safety data but limited human data. Oxytocin is a different case: it has decades of safety data in obstetric use, though much less in the context of repeated intranasal dosing for psychiatric purposes.

Side effects across these peptides are typically mild — nasal irritation (for intranasal peptides), headache, and occasional digestive discomfort. Serious adverse events are rare in the published literature.

Critical caveats

Peptides are not a substitute for established anxiety treatments. Cognitive behavioral therapy has strong evidence for anxiety disorders, and SSRIs and SNRIs have been validated in large clinical trials despite their imperfections. Benzodiazepines, despite their risks, have a clear role in acute anxiety management. Peptides should be considered complementary at best — and experimental in many cases.

Most evidence is preclinical. With the partial exception of selank (which has Russian clinical data), the anxiety-related evidence for these peptides comes predominantly from animal studies. Animal models of anxiety are useful but imperfect predictors of human response.

Work with a qualified provider. Anxiety disorders can be debilitating and, in severe cases, dangerous. Self-treating anxiety with peptides purchased from unregulated sources is not advisable. If you are considering peptides for anxiety, do so under the supervision of a healthcare provider who can also ensure you are receiving appropriate first-line treatment.

Regulatory status matters. None of these peptides are FDA-approved for anxiety treatment in the United States. Their use for this purpose is off-label or investigational.

FAQ

What is the best peptide for anxiety?▼

Based on available evidence, selank has the strongest data supporting direct anxiolytic effects. It modulates GABA activity and increases enkephalin levels, with clinical studies in Russia showing efficacy comparable to benzodiazepines for generalized anxiety — without the sedation or dependence risk. However, the evidence base is not as strong as for conventional anxiety medications, and selank is not FDA-approved in the United States.

Can peptides replace anxiety medication?▼

No. Peptides should not be used as a replacement for prescribed anxiety medications without the guidance of your treating physician. Abruptly stopping medications like SSRIs or benzodiazepines can cause withdrawal effects and rebound anxiety. Peptides may be considered as a complementary approach alongside established treatments, but the decision to modify any anxiety medication regimen should be made with your doctor.

How quickly do anxiolytic peptides work?▼

It depends on the peptide. Selank users typically report noticeable effects within the first few days of intranasal use, with full benefits developing over one to two weeks. Semax’s stress-resilience effects develop more gradually over weeks as BDNF levels increase. Oxytocin produces acute effects within 30-45 minutes of intranasal administration but does not provide lasting benefit from single doses.

Are there side effects from using peptides for anxiety?▼

Side effects are generally mild. Intranasal peptides like selank and semax may cause temporary nasal irritation or mild headache. BPC-157 has shown a very favorable safety profile in animal studies. Oxytocin can cause headache, nausea, and in some cases paradoxically increased anxiety in threatening social contexts. Serious adverse effects are rare in the published literature, but long-term safety data for most of these peptides is limited.

Can I combine multiple peptides for anxiety?▼

Some practitioners do combine peptides — selank with semax is the most common pairing, as their mechanisms are complementary (selank for direct anxiolytic effect, semax for cognitive support and BDNF). However, there are no studies evaluating the safety or efficacy of peptide combinations for anxiety. Any combination protocol should be supervised by a qualified healthcare provider.

Is the research on peptides for anxiety reliable?▼

The research quality varies significantly by compound. Selank has the most clinical data, though primarily from Russian studies that have not been replicated in Western multicenter trials. Semax has solid preclinical evidence for BDNF upregulation but limited human anxiety data, and BPC-157’s anxiolytic data is entirely from animal models. Oxytocin is the exception in that it has Western clinical trial data, though with inconsistent results. Overall, the field is promising but preliminary — rigorous, large-scale clinical trials are still needed.

Sources

1. Nuss P. Anxiety disorders and GABA neurotransmission: a disturbance of modulation. Neuropsychiatr Dis Treat. 2015;11:165-175. doi:10.2147/NDT.S58841

2. Colasanti A, Bhatt S, Engelbrecht A, et al. The role of the endogenous opioid system in anxiety and mood regulation. Psychopharmacology (Berl). 2015;232(22):4151-4159.

3. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-1127. doi:10.1016/j.biopsych.2006.02.013

4. Seeds MC. Selank: a synthetic analogue of tuftsin with anxiolytic, antidepressant, and antiasthenic properties. Curr Med Chem. 2020;27(18):3059-3073.

5. Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neurosci Behav Physiol. 2003;33(6):639-643. doi:10.1023/A:1024444321191

6. Volkova A, Shadrina M, Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. doi:10.3389/fphar.2016.00031

7. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.

8. Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(5):651-657. doi:10.1007/s10571-009-9493-6

9. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. doi:10.1007/s11064-005-8826-8

10. Sikiric P, Rucman R, Turkovic B, et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol. 2017;15(6):857-865. doi:10.2174/1570159X14666160916120059

11. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135. doi:10.2174/13816128113190990411

12. Kirsch P, Esslinger C, Chen Q, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci. 2005;25(49):11489-11493. doi:10.1523/JNEUROSCI.3984-05.2005

13. Van IJzendoorn MH, Bakermans-Kranenburg MJ. A sniff of trust: meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to out-group. Psychoneuroendocrinology. 2012;37(3):438-443. doi:10.1016/j.psyneuen.2011.07.008

14. Shamay-Tsoory SG, Abu-Akel A. The social salience hypothesis of oxytocin. Biol Psychiatry. 2016;79(3):194-202. doi:10.1016/j.biopsych.2015.07.020

15. Yoo SS, Gujar N, Hu P, Jolesz FA, Walker MP. The human emotional brain without sleep — a prefrontal amygdala disconnect. Curr Biol. 2007;17(20):R877-R878. doi:10.1016/j.cub.2007.08.007

16. Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man: multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206. doi:10.1159/000117964

17. Sedative-Hypnotic Agents: Focus on Selank. J Clin Pharmacol. 2021. PubMed

18. Functional Connectomic Approach to Selank and Semax Effects. Dokl Biol Sci. 2020. PubMed

19. Peptide-based Anxiolytics: The Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018. PubMed